Can genetic variants explain the individual courses of the disease with or without severe complications? These and related questions will be investigated in the EPI-Dx project by collecting data from serological, genetic and PCR tests. Despite intensive research into all aspects of COVID-19 disease and pandemic (COronaVIrus Disease 2019), many questions of immunisation and epidemiology remain unanswered. In particular, questions about the development of immunity and infectivity are difficult to research due to the fact that transmission appears to be particularly strong before the onset of symptoms. Reliable findings on the development of immunity even before vaccines are available are therefore of utmost importance for the ability to act in health policy. The question of under which circumstances one can expect a mild or severe course of COVID-19 beyond the so-called risk groups is still unknown. Genetic dispositions are also still part of the research.
Diagnostics can make a major contribution here if differential data are collected in good time and in sufficient depth, and if they are as complete as possible. In this context, complete means: